Utente:OppidumNissenae/Sandbox020: differenze tra le versioni

Versione delle 12:05, 19 apr 2021

Versione delle 12:11, 19 apr 2021

Riga 135:

* titolo di anticorpi anti-fattore piastrinico 4 (PF4), eseguito mediante saggi di immunoassorbimento enzimatico ([[ELISA]]).<ref name="urlPathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination | NEJM"/><ref name="urlwww.simit.org">{{cite web | url = https://www.simit.org/images/ricerca_covid/RICERCA%20BIBLIOGRAFICA%20COVID%2019%204042021.pdf | title = RICERCA BIBLIOGRAFICA COVID 19 SETTIMANA 29.03 – 04.04.2021| author = | authorlink = | coauthors = | date = | format = | work = | publisher = www.simit.org | pages = | language = it| archiveurl = | archivedate = | quote = | accessdate = }}</ref><ref name="Nevzorova Mordakhanova Daminova Ponomareva p. ">{{cite journal | last=Nevzorova | first=Tatiana A. | last2=Mordakhanova | first2=Elmira R. | last3=Daminova | first3=Amina G. | last4=Ponomareva | first4=Anastasia A. | last5=Andrianova | first5=Izabella A. | last6=Le Minh | first6=Giang | last7=Rauova | first7=Lubica | last8=Litvinov | first8=Rustem I. | last9=Weisel | first9=John W. | title=Platelet factor 4-containing immune complexes induce platelet activation followed by calpain-dependent platelet death | journal=Cell Death Discovery | publisher=Springer Science and Business Media LLC | volume=5 | issue=1 | date=2019-06-24 | issn=2058-7716 | doi=10.1038/s41420-019-0188-0 | page=}}</ref>

* livelli sierici di anticorpi contro gli antigeni SARS-CoV-2, inclusa la proteina spike, il dominio di legame del recettore (RBD) e la proteina nucleocapsidica.<ref name="urlPathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination | NEJM"/>

* D-dimero (molto elevato)<ref name="urlPathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination | NEJM"/> (molto più alto di quanto ci si aspetterebbe in pazienti con [[tromboembolia venosa acuta]], tipicamente osservati in pazienti con cancro).<ref name="urlPathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination | NEJM"/><ref name="Paneesha Cheyne French Bacchu 2006 pp. 85–90">{{cite journal | last=Paneesha | first=S. | last2=Cheyne | first2=E. | last3=French | first3=K. | last4=Bacchu | first4=S. | last5=Borg | first5=A. | last6=Rose | first6=P. | title=High D-dimer levels at presentation in patients with venous thromboembolism is a marker of adverse clinical outcomes | journal=British Journal of Haematology | publisher=Wiley | volume=135 | issue=1 | year=2006 | issn=0007-1048 | doi=10.1111/j.1365-2141.2006.06260.x | pages=85–90}}</ref><ref name="Bjøri Johnsen Hansen Braekkan pp. 917–924">{{cite journal | last=Bjøri | first=E. | last2=Johnsen | first2=H. S. | last3=Hansen | first3=J.-B. | last4=Braekkan | first4=S. K. | title=D-dimer at venous thrombosis diagnosis is associated with risk of recurrence | journal=Journal of Thrombosis and Haemostasis | publisher=Wiley | volume=15 | issue=5 | date=2017-02-24 | issn=1538-7933 | doi=10.1111/jth.13648 | pages=917–924}}</ref>

{{citazione|.... lo sviluppo di anticorpi anti-PF4 attivanti le piastrine patologiche, non correlati all'uso della terapia con eparina, potrebbe essere associato alla vaccinazione contro SARS-CoV-2.|Marie Scully, MD, et al.,<ref name="urlPathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination | NEJM"/>| ...the development of pathologic platelet-activating anti-PF4 antibodies, unrelated to the use of heparin therapy, could be associated with vaccination against SARS-CoV-2.|lingua = en}}